Table of Contents
ISRN Cardiology
Volume 2012 (2012), Article ID 692761, 8 pages
http://dx.doi.org/10.5402/2012/692761
Clinical Study

Impact of Dual Antiplatelet Therapy with Proton Pump Inhibitors on the Outcome of Patients with Acute Coronary Syndrome Undergoing Drug-Eluting Stent Implantation

Division of Cardiology and Post-Graduate School of Cardiology, Center for the Early Diagnosis of Preclinical and Multifocal Atherosclerosis and for the Secondary Prevention, University Hospital “P. Giaccone” of the University of Palermo, 127-90127 Palermo, Italy

Received 21 March 2012; Accepted 7 May 2012

Academic Editors: J. Mansourati and J. M. Perez-Pomares

Copyright © 2012 Francesca Macaione et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Iakovou, T. Schmidt, E. Bonizzoni et al., “Incidence, predictors and outcome of thrombosis after succesful implantation of drug-eluting stents,” JAMA, vol. 293, no. 17, pp. 2126–2130, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. C. L. Grines, R. O. Bonow, D. E. Casey et al., “Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians,” Circulation, vol. 115, no. 6, pp. 813–818, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Yusuf, F. Zhao, S. R. Mehta, S. Chrolavicius, G. Tognoni, and K. K. Fox, “Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation,” The New England Journal of Medicine, vol. 345, no. 7, pp. 494–502, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. F. K. L. Chan, J. Y. L. Ching, and L. C. T. Hung, “Clopidogrel versus aspirin and esomeprazole to prevent recurrent ucler bleeding,” The New England Journal of Medicine, vol. 352, no. 3, pp. 338–344, 2005. View at Google Scholar · View at Scopus
  5. P. M. Ho, T. M. Maddox, and L. Wang, “Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome,” JAMA, vol. 301, no. 9, pp. 937–944, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. D. N. Juurlink, T. Gomes, D. T. Ko et al., “A population-based study of the drug interaction between proton pump inhibitors and clopidogrel,” CMAJ, vol. 180, no. 7, pp. 713–718, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Sibbing, T. Morath, J. Stegherr et al., “Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel,” Thrombosis and Haemostasis, vol. 101, no. 4, pp. 714–719, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. M. L. O'Donoghue, E. Braunwald, E. M. Antman et al., “Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials,” The Lancet, vol. 374, no. 9694, pp. 989–997, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. V. E. Valkhoff, G. W. 'T Jong, E. M. Van Soest, E. J. Kuipers, and M. C. J. M. Sturkenboom, “Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 1, pp. 77–88, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Banerjee, R. A. Weideman, M. W. Weideman et al., “Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention,” American Journal of Cardiology, vol. 107, no. 6, pp. 871–878, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo et al., “Variability in individual responsiveness to clopidogrel,” Journal of the American College of Cardiology, vol. 49, no. 14, pp. 1505–1516, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Geiger, L. Teichmann, R. Grossmann et al., “Monitoring of clopidogrel action: comparison of methods,” Clinical Chemistry, vol. 51, no. 6, pp. 957–965, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. J. T. Brandt, S. L. Close, S. J. Iturria et al., “Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel,” Journal of Thrombosis and Haemostasis, vol. 5, no. 12, pp. 2429–2436, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. J. L. Mega, S. L. Close, S. D. Wiviott et al., “Cytochrome P-450 polymorphisms and response to clopidogrel,” The New England Journal of Medicine, vol. 360, no. 4, pp. 354–362, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. B. L. Chen, W. Zhang, Q. Li et al., “Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms,” Clinical and Experimental Pharmacology and Physiology, vol. 35, no. 8, pp. 904–908, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. N. S. Abraham, M. A. Hlatky, E. M. Antman et al., “ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use,” Journal of the American College of Cardiology, vol. 56, no. 24, pp. 2051–2066, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Simon, C. Verstuyft, M. Mary-Krause et al., “Genetic determinants of response to clopidogrel and cardiovascular events,” The New England Journal of Medicine, vol. 360, no. 4, pp. 363–375, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Gilard, B. Arnaud, G. Le Gal, J. F. Abgrall, and J. Boschat, “Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin,” Journal of Thrombosis and Haemostasis, vol. 4, no. 11, pp. 2508–2509, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Kahn, “Report of the expert committee on the diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 20, no. 7, pp. 1183–1197, 1997. View at Google Scholar · View at Scopus
  20. World Health Organization, Nutrizional Anemia: Report of a WHO Scientific Group, World Health Organization, Geneva, Switzerland, 1968.
  21. National Kidney Foundation, “K/DOQI: clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” American Journal of Kidney Diseases, vol. 39, pp. 1–237, 2002. View at Google Scholar
  22. J. L. Anderson, C. D. Adams, E. M. Antman et al., “ACC/AHA 2007 guidelines for the management of patients with unstable angina/Non—ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non—ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,” Journal of the American College of Cardiology, vol. 50, no. 7, pp. 652–726, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Thygesen, J. S. Alpert, H. D. White et al., “On behalf of the joint ESC/ACCF/AHA/WHF Task Force for the redifition of myocardial infarction. Universal definition of myocardial infarction,” Circulation, vol. 116, pp. 2643–2653, 2007. View at Google Scholar
  24. J. S. Hochman, J. E. Tamis, T. D. Thompson et al., “Sex, clinical presentation, and outcome in patients with acute coronary syndromes,” The New England Journal of Medicine, vol. 341, no. 4, pp. 226–232, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. S. B. King III, S. C. Smith Jr., J. W. Hirshfeld Jr. et al., “2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association task force on practice guidelines,” Circulation, vol. 117, no. 2, pp. 261–295, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. R. Mehta, S. Yusuf, R. J. G. Peters et al., “Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study,” The Lancet, vol. 358, no. 9281, pp. 527–533, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. S. R. Steinhubl, P. B. Berger, J. Tift Mann et al., “Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial,” JAMA, vol. 288, no. 19, pp. 2411–2420, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. D. L. Bhatt, J. Scheiman, N. S. Abraham et al., “ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents,” Circulation, vol. 118, no. 18, pp. 1894–1909, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Simon, P. G. Steg, M. Gilard et al., “Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the french registry of acute ST-Elevation and Non-ST-Elevation myocardial infarction (FAST-MI) registry,” Circulation, vol. 123, no. 5, pp. 474–482, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. S. D. Wiviott, D. Trenk, A. L. Frelinger et al., “Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial,” Circulation, vol. 116, no. 25, pp. 2923–2932, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. S. D. Wiviott, E. Braunwald, C. H. McCabe et al., “Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial,” The Lancet, vol. 371, no. 9621, pp. 1353–1363, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Rossini, D. Capodanno, G. Musumeci et al., “Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation,” Coronary Artery Disease, vol. 22, no. 3, pp. 199–205, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. R. E. Aubert, R. S. Epstein, J. R. Teagarden et al., “Proton pump inhibitors effect on Clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study,” Circulation, vol. 118, article S815, 2008. View at Google Scholar
  34. I. Tentzeris, R. Jarai, S. Farhan et al., “Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation,” Thrombosis and Haemostasis, vol. 104, no. 6, pp. 1211–1218, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. M. A. Gaglia, R. Torguson, N. Hanna et al., “Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes,” American Journal of Cardiology, vol. 105, no. 6, pp. 833–838, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Gilard, B. Arnaud, J. C. Cornily et al., “Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study,” Journal of the American College of Cardiology, vol. 51, no. 3, pp. 256–260, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. D. J. Angiolillo, C. M. Gibson, S. Cheng et al., “Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies,” Clinical Pharmacology and Therapeutics, vol. 89, no. 1, pp. 65–74, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. X. Q. Li, T. B. Andersson, M. Ahlström, and L. Weidolf, “Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities,” Drug Metabolism and Disposition, vol. 32, no. 8, pp. 821–827, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Cuisset, C. Frere, J. Quilici et al., “Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose. The PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study,” Journal of the American College of Cardiology, vol. 54, no. 13, pp. 1149–1153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Lettino, “Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies?” European Journal of Internal Medicine, vol. 21, no. 6, pp. 484–489, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. US Food and Drug Administration safety alert for human medicinal products clopidogrel (marketed as Plavix) and omeprazole (marketed as Prilosec)—drug interaction, http://www.emea.europa.eu/docs/en_GB/document_library/Public_statement/2010/03/WC500076346.pdf.
  42. P. Barragan, J. L. Bouvier, P. O. Roquebert et al., “Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation,” Catheterization and Cardiovascular Interventions, vol. 59, no. 3, pp. 295–302, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Matetzky, B. Shenkman, V. Guetta et al., “Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction,” Circulation, vol. 109, no. 25, pp. 3171–3175, 2004. View at Google Scholar · View at Scopus